Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

Six patients with progressive B cell non-Hodgkin's lymphoma have been treated with an IgG2a mouse monoclonal antibody (mAb) against the B cell differentiation antigen CD19, with total doses varying from 225 mg to 1000 mg. Free mAb was detected in the serum after doses of 15-30 mg. After the mAb...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Immunology, Immunotherapy Vol. 32; no. 6; pp. 364 - 372
Main Authors:	HEKMAN, A, HONSELAAR, A, VUIST, W. M. J, SEIN, J. J, RODENHUIS, S, TEN BOKKEL HUINHINK, W. W, SOMERS, R, RÜMKE, P, MELIEF, C. J. M
Format:	Journal Article
Language:	English
Published:	Berlin Springer 01-11-1991 Springer-Verlag
Subjects:	Aged Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Antigens, CD19 Antigens, Differentiation, B-Lymphocyte - immunology Antineoplastic agents B-Lymphocytes - drug effects B-Lymphocytes - immunology Binding Sites, Antibody Biological and medical sciences Bone Marrow - drug effects Dose-Response Relationship, Immunologic Drug Administration Schedule Female Fluorescent Antibody Technique Humans Immunotherapy Lymph Nodes - drug effects Lymphoma, B-Cell - immunology Lymphoma, B-Cell - therapy Male Medical sciences Middle Aged Original Pharmacology. Drug treatments Human Treatment Lymphoproliferative syndrome Immunotherapy Malignant hemopathy B-Lymphocyte Monoclonal antibody Lymphoma
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Six patients with progressive B cell non-Hodgkin's lymphoma have been treated with an IgG2a mouse monoclonal antibody (mAb) against the B cell differentiation antigen CD19, with total doses varying from 225 mg to 1000 mg. Free mAb was detected in the serum after doses of 15-30 mg. After the mAb infusions the number of circulating tumour cells was temporarily reduced, but in some cases antibody-coated cells remained in the circulation for several days. mAb penetrated to extravascular tumour sites; in general higher doses were required to saturate cells in the lymph nodes than to sensitize tumour cells in the bone marrow. mAb doses of up to 250 mg were given i.v. over 4 h without major toxicity. One patient twice achieved a partial remission after two periods of mAb treatment with an 8-month interval; the second remission lasted for 9 months. One patient showed a minor response. None of the patients made antibodies against the mouse immunoglobulin. Serum immunoglobulin levels were followed as a measure of the function of the normal B cell compartment; no significant changes were seen up to 6 months after mAb treatment.
ISSN:	0340-7004 1432-0851
DOI:	10.1007/BF01741331